Acquisition Will Extend CARBOGEN AMCIS’ Offerings for Drug Products16 January 2012
BUBENDORF, Switzerland (January 16, 2012) — Today, Switzerland-based CARBOGEN AMCIS AG, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced the acquisition of Creapharm Parenterals, a subsidiary of France-based Creapharm Group. Creapharm Parenterals (formerly MP5), is a contract development and manufacturing organization (CDMO) specializing in liquid, semi-solid and injectable aseptic dosage forms. As part of this acquisition, Creapharm Parenterals has changed its name to CARBOGEN AMCIS SAS.
"This exciting transaction further strengthens CARBOGEN AMCIS’ service offerings, enabling us to provide our customers with a complete and reliable manufacturing solution from process development to the supply of pharmaceutical substances and formulated products," says Mark Griffiths, CEO of CARBOGEN AMCIS.
The acquisition will extend CARBOGEN AMCIS’ comprehensive range of development and manufacturing services by adding complementary formulation, lyophilization services and sterile GMP capabilities for the fast supply of drug products, including highly-potents, for preclinical studies and clinical trials (Phase I, II & III). "This move reflects our determination to continue to position CARBOGEN AMCIS as a leading service provider for early phase development projects and niche scale commercial products within the Dishman Group of Companies" added Jay Vyas, Managing Director of the Dishman Group and owner of CARBOGEN AMCIS.
Creapharm Parenterals brings over 10 years of expertise in the supply of Investigational Medicinal Products (IMP), with more than 300 batches and 145 clinical batches produced since 2000. The company employs 16 highly-qualified specialists and operates a GMP manufacturing site in Riom, France. Creapharm’s plant was successfully inspected in 2009 by the French Health Agency (Agence Francaise de Sécurité Sanitaire des Produits de Santé - AFSSAPS).
Through this acquisition, CARBOGEN AMCIS has added the following services for injectable, liquid and semi-solid pharmaceutical forms:
- Formulation of new products
- Optimization of existing formulation
- Development and optimization of lyophilization cycles
- Parenterals production of preclinical and clinical batches (Phase I, II and III)
- Aseptic process validation (Media Fill Testing)
- GMP capabilities for the development of injectables in liquid or freeze-dried forms
- Aseptic filling in vials, syringes, cartridges and infusion bags
"We believe that the combined capabilities and services of our two companies present a one-stop solution to pharmaceutical, biotech and virtual pharmaceutical companies looking for a single reliable partner that can provide API and drug product development for preclinical and clinical studies," adds Maxime Laugier, Development and Projects Director at Creapharm Parenterals.
CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development, allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.
Creapharm Parenterals (formerly MP5) is a contract manufacturer of clinical trial materials focused on formulation, aseptic filling, and lyophilization of APIs, cytotoxics and other high potency drugs, as well as biologics. Creapharm Parenterals has produced hundreds of batches since its inception over 10 years ago and is compliant EU (EMEA) GMP. Creapharm Parenterals is registered by the French Health Agency (AFSSAPS) for the manufacture of clinical trial materials according to the EU-GMP Annex 13 under authorization number M02/150. Creapharm Parenterals is committed to quality and has Qualified Persons (QPs) on staff to release product for use in the EU. Creapharm Parenterals uses proprietary isolator technology to ensure the highest level of sterility assurance as well as protect technicians -during the manufacturing process. As a result of this acquisition, Creapharm Parenterals has changed name to CARBOGEN AMCIS SAS.
Creapharm (www.creapharm.com) is a leading European clinical supplier. Creapharm offers Phase I-IV clinical manufacturing, packaging, labeling, as well as clinical inventory management, and cold chain distribution through a large network of worldwide depots to meet clients’ diverse clinical trial needs. Creapharm has produced over 6,000 batches since its inception.
Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and commercial API manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.